Author

Milad Moradi

Observed name: Moradi, Milad

Institution: Stem Cell Technology Research Center

Observed institution: Stem Cell Technology Research Center

ORCID: 0000-0002-2584-458X

Observed ORCID: 0000-0002-2584-458X

OpenAlex ID: A5001874178

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial

2022 · Mohammadreza Ahi, Ramin Hamidi Farahani, et al. · Vaccines · 7

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

2023 · Fatemeh Gholami, Ramin Hamidi Farahani, et al. · BMC Infectious Diseases · 4

Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial

2023 · Masoud Solaymani-Dodaran, Pouria Basiri, et al. · Virology Journal · 2

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

2023 · Akram Ansarifar, Ramin Hamidi Farahani, et al. · Vaccine X

Works count: 9

Citation count: 13

H-index: 2

I10-index: